US · RDHL
RedHill Biopharma Ltd.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Tel Aviv 6473921
- Website
- redhillbio.com
Price · as of 2024-12-31
$1.09
Market cap 3.23M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $389.94 | +35,839.17% |
| Intrinsic Value(DCF) | $1.26 | +16.13% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | $10,750.00 | $6,192.56 | $829.56 | $0.00 | $20,563.48 |
| 2013 | $13,950.00 | $5,957.56 | $16.33 | $0.00 | $13,445.90 |
| 2014 | $13,640.00 | $16,628.90 | $2,970,598.59 | $0.00 | $0.00 |
| 2015 | $11,910.00 | $6,299.45 | $1,557.31 | $0.00 | $83,288.22 |
| 2016 | $10,340.00 | $4,194.89 | $1,097.41 | $0.00 | $0.00 |
| 2017 | $6,120.00 | $3,086.23 | $37,082.38 | $0.00 | $0.00 |
| 2018 | $7,740.00 | $6,066.78 | $10,990,477.04 | $0.00 | $0.00 |
| 2019 | $4,710.00 | $1,897.24 | $207.82 | $0.00 | $11,106.94 |
| 2020 | $7,900.00 | $3,206.54 | $1,426,384.95 | $0.00 | $0.00 |
| 2021 | $1,730.00 | $712.04 | $75,842.33 | $0.00 | $0.00 |
| 2022 | $198.00 | $3,665.26 | $0.00 | $0.00 | $10,792.86 |
| 2023 | $13.38 | $105.46 | $6.54 | $234.73 | $0.00 |
| 2024 | $3.15 | $389.94 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates RedHill Biopharma Ltd.'s (RDHL) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $389.94
- Current price
- $1.09
- AI upside
- +35,839.17%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.26
+16.13% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RDHL | RedHill Biopharma Ltd. | $1.09 | 3.23M | +35,839% | +16% | — | — | -0.94 | -1.66 | 0.97 | -0.46 | — | -0.76 | 60.31% | -181.69% | -102.80% | 632.60% | 242.32% | -40.24% | -0.08 | -265.69 | 0.54 | 0.37 | 0.56 | -11522.00% | 2317.00% | -7383.00% | -120.72% | -0.42 | 155.51% | 0.00% | 0.00% | 0.00% | -0.24 | -0.37 | 0.44 | -34.89 |
| AKAN | Akanda Corp. | $1.04 | 151.47K | +9,512% | +862% | — | +18,953% | -6.36 | 6.09 | 31.14 | -7.45 | — | 6.11 | 24.91% | -523.80% | -489.57% | -1830.03% | -998.53% | -48.90% | 0.08 | -43.78 | 1.39 | 1.28 | 1.15 | -9355.00% | -6127.00% | 30467.00% | -23.33% | -1.09 | -1384.96% | 0.00% | 0.00% | 28.41% | -5.15 | -3.71 | 26.97 | -7.37 |
| BGMS | Bio Green Med Solution, I… | $0.98 | 1.89M | +2,199,316% | +3,759,305% | — | +3,987,072% | -0.07 | -0.38 | 19.24 | 0.19 | — | -0.38 | 100.00% | -27916.28% | -26074.42% | 1431.01% | 278.96% | -173.84% | 0.00 | — | 0.59 | 0.54 | 0.26 | -9219.00% | -8976.00% | -5043.00% | -965.78% | -1.27 | 198.63% | 0.00% | 0.00% | 0.00% | 0.19 | 0.29 | -53.71 | -160.64 |
| BNBX | BNB Plus Corp. | $0.71 | 910.41K | — | — | — | — | -0.10 | 0.67 | 0.73 | -0.01 | — | 0.67 | 39.26% | -750.92% | -709.46% | — | — | — | 0.08 | — | 0.91 | 0.77 | 0.09 | — | — | — | -826.25% | -5.08 | — | 0.00% | 0.00% | 0.00% | 0.00 | -0.01 | 0.04 | -130.76 |
| CNSP | CNS Pharmaceuticals, Inc. | $3.11 | 1.79M | — | — | — | — | -0.68 | 1.63 | — | -0.27 | — | 1.63 | 0.00% | — | — | -1703.39% | 642.50% | -285.68% | 0.05 | -924.50 | 3.43 | 2.91 | 0.41 | -3522.00% | — | 2102.00% | -169.67% | -6.78 | 738.03% | 0.00% | 0.00% | 58.36% | -0.27 | -0.23 | — | -15.99 |
| FLGC | Flora Growth Corp. | $7.79 | 4.23M | +647% | +31% | — | +112% | -19.62 | 69.19 | 5.24 | -20.59 | — | -1289.54 | 21.00% | -26.73% | -26.73% | -291.50% | -345.04% | -63.82% | 1.09 | -74.68 | 1.05 | 0.71 | 0.07 | -8226.00% | -2178.00% | -3964.00% | -1.66% | -0.27 | -113.30% | 0.00% | 0.00% | 0.14% | -19.55 | -60.19 | 5.23 | 0.49 |
| GCTK | GlucoTrack, Inc. | $1.55 | 879.56K | — | — | — | — | -0.36 | -0.63 | — | -0.13 | — | -0.63 | 0.00% | — | — | 461.02% | 149.59% | -417.03% | -0.02 | -24.95 | 4.52 | 4.41 | 0.24 | -25864.00% | — | 9204.00% | -152.95% | -9.80 | 129.51% | 0.00% | 0.00% | 12.80% | -0.20 | -0.23 | — | -38.18 |
| IMCC | IM Cannabis Corp. | $0.68 | 2.1M | +52,536% | +13% | — | — | -0.54 | 1.20 | 0.12 | -3.82 | -39.70 | -1.32 | 15.64% | -18.94% | -19.59% | -119.43% | -38.57% | -26.75% | 3.44 | -2.29 | 0.67 | 0.50 | -2.79 | 135.00% | 1071.00% | -8576.00% | -19.57% | -0.03 | -5.05% | 0.00% | 0.00% | 0.00% | -2.29 | -19.02 | 0.43 | -8.98 |
| JAGX | Jaguar Health, Inc. | $0.89 | 1.93M | +7,724% | +550% | — | — | -0.11 | 0.58 | 0.36 | -0.89 | — | -0.38 | 83.27% | -263.76% | -329.30% | -637.50% | -86.37% | -74.93% | 5.01 | -133.47 | 1.63 | 0.49 | -0.78 | -9513.00% | 1975.00% | -1091.00% | -697.04% | -1.49 | -82.96% | 0.00% | 0.00% | 49.45% | -1.06 | -1.11 | 2.80 | -10.43 |
| MSPR | MSP Recovery, Inc. | $0.04 | 537.2K | +14,182% | +17,977% | — | — | -0.01 | 0.14 | 0.76 | -1.22 | -0.01 | -0.01 | 47.36% | -6982.79% | -1975.45% | -834.83% | -139.81% | -61.30% | 7.90 | -3.03 | 0.01 | 0.01 | -1.20 | 12779.00% | 13685.00% | -6014.00% | -119.26% | -0.01 | -1.83% | 0.00% | 0.00% | 0.00% | -0.62 | -47.84 | 43.63 | -3.28 |
| SXTP | 60 Degrees Pharmaceutical… | $3.11 | 2.51M | +12,794% | +37,941,033% | — | — | -0.09 | 0.18 | 1.17 | 0.32 | 0.00 | 0.18 | 36.67% | -1598.97% | -1308.01% | -178.66% | -524.57% | -117.49% | 0.04 | -1227.87 | 3.25 | 2.34 | 0.19 | 185263.00% | 13961.00% | 2512.00% | -822.00% | -3.41 | -314.75% | 0.00% | 0.00% | 0.00% | 0.26 | 0.43 | -4.15 | -14.30 |
About RedHill Biopharma Ltd.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
- CEO
- Dror Ben-Asher
- Employees
- 35
- Beta
- 4.88
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.26 ÷ $1.09) − 1 = +16.13% (DCF, example).